Showing 6211-6220 of 9137 results for "".
- Data Show Continuous Response to LEO's Tralokinumab in Adults with ADhttps://practicaldermatology.com/news/data-show-continuous-response-to-leos-tralokinumab-in-adults-with-ad/2460933/After two years of continuous treatment with tralokinumab, adult patients with moderate-to-severe atopic dermatitis maintained improvements in signs and symptoms, itch severity, and sleep interference, according to interim findings from the Phase 3 ECZTEND trial presented as an oral presenta
- It's Eczema Awareness Monthhttps://practicaldermatology.com/news/its-eczema-awareness-month/2460932/Recognizing that the daily impact and overall burden of eczema for each individual can differ greatly from person to person and within a person's lifetime, the
- Castle Creek, Mayo Clinic to Collaborate on Therapies for Rare Genetic Connective Tissue Disordershttps://practicaldermatology.com/news/castle-creek-mayo-clinic-to-collaborate-on-therapies-for-rare-genetic-connective-tissue-disorders/2460930/Castle Creek Biosciences, Inc. is collaborating with Mayo Clinic to advance discovery and pre-clinical development of investigational gene therapy candidates for the treatment of osteogenesis imperfecta (OI) and classical Ehlers-Danlos syndrome (EDS). Neither rare genetic connective tissue disord
- Bimekizumab Performs Well in Psoriasis with Results Lasting through Two Yearshttps://practicaldermatology.com/news/bimekizumab-performs-well-in-psoriasis-with-results-lasting-through-two-years/2460929/Interim results from the BE BRIGHT open-label extension (OLE) study showed clinical responses observed in bimekizumab-treated psoriasis patients during the first 16 weeks of BE SURE were sustained through to two years of treatment with continuous maintenance dosing, UCB reports. T
- Happy 25th Birthday Restylane!https://practicaldermatology.com/news/happy-25th-birthday-restylane/2460928/Galderma’s Restylane is celebrating 25 years on the market. Since launching in Europe in 1996, Restylane has celebrated many milestones across the globe. This includes the first approval for use by the U.S. Food and Drug Administration (FDA) in 2003 and in China by the
- FDA Takes Steps Aimed at Improving Quality, Safety and Efficacy of Sunscreenshttps://practicaldermatology.com/news/fda-takes-steps-aimed-at-improving-quality-safety-and-efficacy-of-sunscreens/2460926/The U.S. Food and Drug Administration today took steps aimed at improving the quality, safety, and efficacy of sunscreens as part of its implementation of new authorities for certain over-the-counter (OTC) drugs. In the short term, these new authorities essentially preserve status
- Dermavant: First Patient Dosed in Phase 3 Study of Tapinarof in ADhttps://practicaldermatology.com/news/dermavant-first-patient-dosed-in-phase-3-study-of-tapinarof-in-ad/2460925/The first patient has been dosed in the Phase 3, double-blind, vehicle-controlled pivotal study of tapinarof for the treatment of atopic dermatitis (AD). Tapinarof is an investigational, novel, therapeutic aryl hydrocarbon receptor modulating agent, in development by
- Mayne Pharma's Lexette Approved for Adolescentshttps://practicaldermatology.com/news/mayne-pharmas-lexette-approved-for-adolescents/2460921/Lexette® (halobetasol propionate) foam, 0.05% from Mayne Pharma is now approved for the treatment of plaque psoriasis in patients aged 12 years and older. FDA approved Lexette in 2018 for use in adults. Approval in adolescents is
- Incyte's Opzelura is First Topical JAK Inhibitor Approved in UShttps://practicaldermatology.com/news/incyts-opzelura-is-first-topical-jak-inhibitor-approved-in-us/2460919/Opzelura™ (ruxolitinib) cream from Incyte is now the first and only topical formulation of a JAK inhibitor approved in the United States. FDA approved Opzelura for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis
- Accure Acne, Inc. Appoints Jeffrey O'Donnell, Sr. to the Boardhttps://practicaldermatology.com/news/accure-acne-inc-announces-the-appointment-of-jeffrey-odonnell-sr-to-the-board/2460918/Jeffrey O'Donnell, Sr. has joined Accure Acne's Board of Directors. Along with Chairman and Founder Christopher Carlton and Founder Ed Barbera, Mr. O'Donnell provides strategic guidance for Accure's i